LATEST ONCOPRESCRIBE UPDATES
Late Breaking Abstract – ASCO 2026: Evidence for Comprehensive PI3K/AKT/mTOR Pathway Inhibition in HR-Positive, HER2-Negative Advanced Breast Cancer
FDA Approves All-Oral Treatment for Newly Diagnosed Acute Myeloid Leukemia
HERIZON-GEA-01 and the Future of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma
Late Breaking Abstract – ASCO 2026: Perioperative Apalutamide Plus ADT in High-Risk Localized and Locally Advanced Prostate Cancer
Late Breaking Abstract – ASCO 2026: Adjuvant Selpercatinib Delivers Landmark Event-Free Survival Benefit in Early-Stage RET Fusion–Positive NSCLC
Late Breaking Abstract – ASCO 2026: Daraxonrasib Redefines Second-Line Treatment for Metastatic Pancreatic Cancer
DATROWAY® Demonstrates Survival Advantage in First-Line Metastatic Triple-Negative Breast Cancer
CheckMate-9ER primary and exploratory findings: baseline characteristics and treatment outcomes, including depth and durability of response with cabozantinib plus nivolumab
NEW REGIMENS ADDED
VYLOY® with mFOLFOX 6 - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin), 5-FU and Leucovorin. Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveVYLOY® with CAPOX - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin) and XELODA® (Capecitabine). Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveENHERTU® - for Breast Cancer
Single Agent ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Ultralow Metastatic Breast CancerOPDIVO® and YERVOY® with Limited Course Chemotherapy - for Non Small Cell Lung Cancer
OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) with 2 cycles of TAXOL® (Paclitaxel) and PARAPLATIN®(Carboplatin) - for advanced NSCLCJAYPIRCA® - for Mantle Cell Lymphoma
JAYPIRCA® (Pirtobrutinib) for Mantle Cell Lymphoma
Curbside Consultation
Bottom Ad
Advertisement
Subscribe
